1. Site Top
  2. DesignCell
key visual:DesignCell

DesignCell ®

Treating cancer and other intractable diseases at reasonable cost

  1. Now
    • Cell Survivor Treatment and Regenerative Medicine Clinically Started
  3. 2030
    • The market for cell survivorship treatment and regenerative medicine is growing
  5. 2050

We develop gene modification technology and next-generation automated cell culture technology based on digital x bio fusion to rationalize the cost of advanced medical care, and build a total seamless solution for designed cell pharmaceuticals to overcome intractable diseases such as cancer and realize a society where everyone can live a vibrant life.

Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT

News release overview Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT Harnessing its automated cell culturing and digital technology to overcome intractable diseases Tokyo, 6 July 2023 – Hitachi, Ltd. (TSE: 6501, "Hitachi") an...
H
hitachi-rd-en @ hitachi-rd-en
News ReleaseLife sciencesBackcasting R&DHealthcareWell-beingSociety with 100-year active lifeDesignCellNews & EventsNews Release（Life sciences）News Release Backcasting R&D

ARCALIS and Hitachi Enter Joint Research Agreement on mRNA Sequence Design Technology

ARCALIS, Inc. Hitachi, Ltd. News release overview ARCALIS and Hitachi Enter Joint Research Agreement on mRNA Sequence Design Technology ARCALIS, Inc. (Headquarters: Kashiwa-shi, Chiba; President and CEO: Tomoyuki Fujisawa; hereinafter 'ARCALIS') and Hitachi, Ltd. (Headquarters: Chiyoda-ku, Tokyo;...
H
hitachi-rd-en @ hitachi-rd-en
News ReleaseLife sciencesBackcasting R&DHealthcareSociety with 100-year active lifeDesignCellNews & EventsNews Release（Life sciences）News Release（Healthcare）
See all articles
External announcement

R&D Topics, News Release, Academic conferences, papers, events, etc.

This article is a sponsored article by
''.